FDA approves first-of-a-kind gene therapy for dystrophic epidermolysis bullosa
By Catherine Eckford (European Pharmaceutical Review)
New $1.7b Novartis acquisition to advance novel microRNA inhibitor
By Catherine Eckford (European Pharmaceutical Review)
Eli Lilly to lead oligonucleotide therapy development in new collaboration
By Catherine Eckford (European Pharmaceutical Review)
USP boosts support for AAV-based gene therapy manufacturers
By Catherine Eckford (European Pharmaceutical Review)
QbD for biopharmaceutical product lifecycle management
By Busol Park (Samsung Biologics), Youngsun Kim (Samsung Biologics)